CN110841051A - External-use ginger and white-cord essential oil for treating migraine - Google Patents
External-use ginger and white-cord essential oil for treating migraine Download PDFInfo
- Publication number
- CN110841051A CN110841051A CN201911276697.4A CN201911276697A CN110841051A CN 110841051 A CN110841051 A CN 110841051A CN 201911276697 A CN201911276697 A CN 201911276697A CN 110841051 A CN110841051 A CN 110841051A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- ginger
- white
- migraine
- corydalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 107
- 241000234314 Zingiber Species 0.000 title claims abstract description 47
- 235000006886 Zingiber officinale Nutrition 0.000 title claims abstract description 47
- 235000008397 ginger Nutrition 0.000 title claims abstract description 47
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 42
- 206010027599 migraine Diseases 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 26
- 241000218176 Corydalis Species 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000000605 extraction Methods 0.000 claims description 41
- 238000000926 separation method Methods 0.000 claims description 22
- 241000758794 Asarum Species 0.000 claims description 15
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 15
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 15
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 13
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 13
- 229940116229 borneol Drugs 0.000 claims description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 3
- 241000125175 Angelica Species 0.000 claims 6
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 17
- 241000700159 Rattus Species 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 210000003128 head Anatomy 0.000 description 15
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 239000006187 pill Substances 0.000 description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 229960002748 norepinephrine Drugs 0.000 description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 244000124853 Perilla frutescens Species 0.000 description 6
- 235000004348 Perilla frutescens Nutrition 0.000 description 6
- 238000005452 bending Methods 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 244000061520 Angelica archangelica Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229960002807 flunarizine hydrochloride Drugs 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000009191 jumping Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000017376 neurovascular disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/022—Refining
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/025—Recovery by solvent extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to external ginger white cord essential oil for treating migraine, which can effectively solve the problem of medication for treating the migraine and adopts the technical scheme that the external ginger white cord essential oil comprises the following raw materials: dissolving radix Angelicae Dahuricae essential oil 5-7ml, herba asari essential oil 4-6ml, rhizoma Zingiberis recens essential oil 4-6ml, herba Menthae essential oil 4-6ml, rhizoma corydalis essential oil 2.5-3.5ml and Borneolum 5-7g, and mixing; the invention has the advantages of rich raw materials, easy production and preparation, low cost and good use effect, develops a new medicine for treating migraine and has remarkable economic and social benefits.
Description
Technical Field
The invention relates to a medicine, in particular to a ginger and white thread essential oil for treating migraine by external application.
Background
Migraine (migrine) is the most common clinical primary headache type, mostly has a side headache, generally lasts for 4-72 hours, can be accompanied by nausea and vomiting, can be aggravated by light and sound stimulation or daily activities, and can relieve the headache in quiet environment and rest. Migraine is a common chronic neurovascular disease, the disease mostly occurs in children and adolescence, the middle and young age reaches the peak of the disease, women are common, the proportion of male and female patients is about 1: 2-3, the prevalence rate in the population is 5% -10%, the disease is often inherited, periodic attacks are caused by the sudden attack of pain on one side of the head, or left or right, or eye and teeth, and the pain is stabbing pain, distending pain or jumping pain, the pain stops as usual, the attack is repeated, and the stubborn disease is difficult to heal, the physical and mental health of people is greatly influenced, and therefore, how to treat the migraine is always a concern for people. Although various medicines for treating migraine exist, such as Zhengtian pill, flunarizine hydrochloride capsule and the like, the use and the curative effect are not satisfactory for various reasons, so the improvement and innovation of the medicines for treating the migraine are technical problems to be solved seriously.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide the externally applied rhizoma zingiberis recens-white cable essential oil for treating migraine, which can effectively solve the problem of medication for treating migraine.
The technical scheme for solving the problem is that the external ginger white cord essential oil for treating migraine is prepared from the following raw materials: dissolving radix Angelicae Dahuricae essential oil 5-7ml, herba asari essential oil 4-6ml, rhizoma Zingiberis recens essential oil 4-6ml, herba Menthae essential oil 4-6ml, rhizoma corydalis essential oil 2.5-3.5ml and Borneolum 5-7g, and mixing; wherein:
the radix angelicae essential oil is prepared by crushing radix angelicae into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting fluid, wherein the weight-to-volume ratio of liquid to material is 1: 10-20, the weight-to-volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the angelica essential oil is obtained;
the asarum essential oil is prepared by crushing asarum into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain asarum essential oil;
the ginger essential oil is prepared by crushing ginger into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the ginger essential oil;
the mint essence4ml of oil is prepared by crushing mint into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the mint ginseng essential oil;
the rhizoma corydalis essential oil is prepared by crushing rhizoma corydalis into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2And (3) fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the corydalis essential oil.
The borneol is borneol in accordance with the national formulary.
The invention has the advantages of rich raw materials, easy production and preparation, low cost and good use effect, develops a new medicine for treating migraine and has remarkable economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
The invention may be embodied in the form of the following examples.
Example 1
In the specific implementation of the invention, the ginger white cord essential oil for treating migraine through external use is prepared from the following raw materials: 6ml of angelica essential oil, 5ml of asarum essential oil, 5ml of ginger essential oil, 5ml of mint essential oil, 3ml of corydalis essential oil and 6g of borneol, and dissolving and uniformly mixing to prepare the traditional Chinese medicine composition; wherein:
the radix angelicae essential oil is prepared by crushing radix angelicae into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting fluid, wherein the weight-to-volume ratio of liquid to material is 1: 10-20, the weight-to-volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the angelica essential oil is obtained;
the asarum essential oil is prepared by crushing asarum into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, and the extraction temperature is 42The asarum essential oil is obtained at the temperature of 50 ℃ below zero, the extraction pressure of 20-25 MPa, the separation temperature of 50-60 ℃, the separation pressure of 4.5-5.5 MPa and the extraction time of 1.5-2.5 h;
the ginger essential oil is prepared by crushing ginger into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the ginger essential oil;
the mint essential oil 4ml is prepared by crushing mint into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the mint ginseng essential oil;
the rhizoma corydalis essential oil is prepared by crushing rhizoma corydalis into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2And (3) fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the corydalis essential oil.
The borneol is borneol in accordance with the national formulary.
Example 2
In specific implementation, the invention provides a ginger white cord essential oil for external use for treating migraine, which is characterized by comprising the following raw materials: 5.5ml of angelica essential oil, 5.5ml of asarum essential oil, 4.5ml of ginger essential oil, 5.5ml of mint essential oil, 2.8ml of corydalis essential oil and 6.5g of borneol, and the preparation method is the same as that of example 1.
Example 3
In specific implementation, the invention provides a ginger white cord essential oil for external use for treating migraine, which is characterized by comprising the following raw materials: 6.5ml of angelica essential oil, 4.5ml of asarum essential oil, 5.5ml of ginger essential oil, 4.5ml of mint essential oil, 3.2ml of corydalis essential oil and 5.5g of borneol, and the preparation method is the same as that of example 1.
The ginger and white thread essential oil is used for treating headache caused by wind-cold invading the upper part and emptying. In the formula, radix angelicae dahuricae can dispel wind and relieve pain, and is good at treating headache due to yangming meridians, and Li Gao says that radix angelicae dahuricae is a menstruum-inducing medicine of yangming meridians and is a monarch medicine thereof; the asarum has the effects of dispelling cold and relieving pain, is good at treating shaoyang channel headache, the borneol is light and ascends, and can enhance the effects of dispelling wind and relieving pain and clearing head and eyes when being used together with the mint, and the medicines are used together and are used as ministerial medicines together; corydalis tuber is a good medicine for promoting blood circulation, promoting qi circulation and relieving pain, can be specially used for treating various pains in the upper and lower parts of the whole body, and is a commonly used analgesic; the pungent and warm nature of Sheng Jiang can not only dispel wind and cold, but also prevent the cold and cool nature of the drugs such as borneol, and they are used as adjuvant drugs. The medicines are used together to achieve the effects of clearing head and eyes, promoting qi circulation to relieve pain, dispelling wind and dispelling cold.
The product of the invention has very good effect through experiments and clinical application, and the related data are as follows (taking the example 1 as an example):
first, animal experiment
1 materials of the experiment
1.1 pharmaceutical Agents
Zhengtian pill: product batch No. 1803056H of Huarun Sanjiu medicine, Inc.; nitroglycerin: product batch number 20180409 of Beijing Yimin pharmaceutical Co., Ltd; physiological saline: henan Kolun pharmaceutical Co., Ltd, product batch number: c218073003-2. The product of example 1 of the invention.
Laboratory apparatus
JM 1000 electronic scale, yuyao inscription weighing and checking equipment limited; model 680 enzyme calibrator, BIO-RAD, USA, model: BIORAD-680; KDC-160HR high speed refrigerated centrifuge, a good division of science and technology Innovation, Inc.
Laboratory animal
SD rat, male, 180~200 Ag, SPF grade, license number: SCXK (lu) 20140007;
quality certification of experimental animals: no. 37009200014820; provided by experimental animals center, Shandong province.
Laboratory license number: SYXK (yu) 20150005.
Experimental methods
2.1 grouping and Molding
Molding: taking 60 SD male rats, normally raising, adapting to environment, randomly taking 12 rats as blankThe groups do not make a model, and the rest are randomly divided into a model group, a Zhengtian pill group and a large and small dosage group of the ginger and rhizoma corydalis essential oil. Administering with ZHENGTIAN pill group before molding for 5d (intragastric administration), and administering with other administration groups for 2d for prevention, and coating essential oil at corresponding positions of rat Fengchi acupoint and Baihui acupoint. After the last administration for 30min, the model group and each administration group were prepared into migraine model by injecting 10mg/kg nitroglycerin subcutaneously into the neck and back. After 3min, the appearance of the behavior changes such as redness of ears, frequent head bending, tail biting, back and forth movement of forelimbs, increase of cage climbing times and the like is regarded as the success of the model building[2]。
And (3) scratching the head, taking 1 time period every 30min from the time of molding, observing the times of scratching the head in each time period after the rat is molded by a method of counting in a continuous time period in a segmented mode from the time of molding. The total number of flexible heads within 1h was continuously observed.
Measurement index
2.2.1 migraine Observation and Scoring
After molding, the number of times of head bending of all rats was observed: and (3) taking 30min as 1 time period, and observing the times of head bending of the rat in the plurality of time periods after the model is made by adopting a method of duration segmented counting. See table 1 for details.
Determination of hormone content in brain homogenate
Injecting nitroglycerin subcutaneously into rats for 1h, anesthetizing with chloral hydrate, taking brain tissue on an ice bench, washing with 0.9% sodium chloride solution to remove superficial blood on the surface, taking 0.5g of brain tissue, adding 0.9% sodium chloride solution to prepare 10% brain tissue homogenate, storing at-80 ℃, and determining the contents of 5-hydroxytryptamine (5-HT), Norepinephrine (NE), epinephrine (E) and Dopamine (DA) in the brain tissue by adopting an enzyme-linked immunoassay method according to the kit instructions.
Statistical processing method
Statistical processing of data using the SPSS 19.0 statistical software package for data analysis, mean. + -. standard deviation for data measurement: (S), comparing among groups by adopting one-factor variance analysis, checking the uniform variance by using a Least Significant Difference (LSD) method, checking the non-uniform variance by using a Games-Howell method, and using Radi for grade dataAnd (5) t testing.
Results of the experiment
3.1 Effect on appearance scores in rat migraine model
TABLE 1 influence of ginger white cord essential oil on behavioral scores (± s) of rat migraine model
| Group of | 0-30min | 30-60min |
| Blank group | 0 | 0 |
| Model set | 36.11±11.10## | 26.11±6.68## |
| Zhengtian pill group | 23.33±7.43** | 23.11±5.51* |
| Ginger and white beefsteak essential oil high-dose group | 29.44±9.98* | 13.67±3.57** |
| Ginger and white beefsteak essential oil small dose group | 28.44±9.23* | 11.89±4.34** |
Note: in comparison to the blank set,## P<0.01，# P<0.05; as compared with model groupP<0.01，*P<0.05
As can be seen from Table 1: the number of times of head bending of the model group is significantly increased (P) compared to the blank group<0.01). Compared with the model group, the Zhengtian pill group can obviously reduce the number of times of head bending of the rat in the 0-30min stage (P)<0.01), the large and small dosage groups of the ginger white cord essential oil can obviously reduce the times of head scratching of rats (P<0.05); in the 30-60min period, the large and small dosage groups of the ginger white cord essential oil can obviously reduce the times of head scratching of rats (P<0.01), Zhengtian pill group can obviously reduce the number of times of head bending of rats (P<0.05）。
Effect on brain homogenate transmitter levels in rat migraine model
TABLE 2 influence of ginger white rope essential oil rats on migraine model brain homogenate 5-HT, NE levels (. + -. s)
| Group of | 5-HT（pg/mL） | NE（pg/mL） |
| Blank group | 41.58±5.85 | 2.56±0.40 |
| Model set | 34.04±3.75## | 1.72±0.22## |
| Zhengtian pill group | 41.55±7.25** | 2.79±0.55** |
| Ginger and white beefsteak essential oil high-dose group | 41.00±9.49* | 2.86±0.37** |
| Ginger and white beefsteak essential oil small dose group | 44.54±10.68** | 2.16±0.40** |
Note: in comparison to the blank set,## P<0.01，# P<0.05; as compared with model groupP<0.01，*P<0.05
From table 2, it is known that: compared with the blank group, the brain homogenate of the model group has obviously reduced levels of 5-HT and NE (P)<0.01); compared with the model group, the small-dose group and the Zhengtian pill group of the ginger and white soxhlet essential oil can obviously increase the 5-HT level of the brain homogenate (P<0.01), the group with large dose of rhizoma zingiberis alba essential oil can obviously increase the 5-HT level of brain homogenate (P<0.05); the large and small dosage groups of the ginger and rhizoma corydalis essential oil and the Zhengtian pill group can obviously increase the NE level of brain homogenate (P<0.01）。
TABLE 3 level of brain homogenate DA, E in rats with ginger white rope essential oil on migraine modelInfluence (± s)
| Group of | DA（pg/mL） | E（pg/mL） |
| Blank group | 35.01±2.93 | 2.62±0.21 |
| Model set | 24.87±4.80## | 2.33±0.23## |
| Zhengtian pill group | 33.22±6.03** | 2.90±0.48** |
| Ginger and white beefsteak essential oil high-dose group | 43.71±7.92** | 2.93±0.54** |
| Ginger and white beefsteak essential oil small dose group | 31.46±4.14** | 2.34±0.35 |
Note: in comparison to the blank set,## P<0.01，# P<0.05; as compared with model groupP<0.01，*P<0.05
From table 3, it is known that: compared with the blank group, the brain homogenate DA and NE levels of the model group are obviously reduced (P is less than 0.01); compared with the model group, the large and small dosage groups and the Zhengtian pill group of the ginger white soyabean essential oil can obviously increase the level of brain homogenate DA (P is less than 0.01); the large dose group and the Zhengtian pill group of the ginger and white soyabean essential oil can obviously increase the NE level of the brain homogenate (P is less than 0.01).
And (3) knotting:
the external application of the ginger white cord essential oil can obviously improve the apparent symptoms and brain homogenate biochemical indexes of a rat model with migraine and has good treatment effect on the rat model with migraine.
Second, clinical experiments
Under the condition that animal experiments ensure safety, the medicine is clinically applied to migraine patients, and a very satisfactory curative effect is obtained, and the specific data are as follows:
migraine is a periodic attack disease, which is characterized in that pain on one side of the head, or left or right, or eyes and teeth, is stabbing pain, distending pain or jumping pain, the pain is stopped as usual, the migraine attacks repeatedly, and the migraine is lingering and difficult to cure.
28 migraine patients, 18 men and 10 women, aged 24-60 years were selected. The groups were randomly divided into 2 groups, namely an observation group and a control group, and 14 cases were used. Inclusion criteria were: meets the diagnosis standard of migraine in the Chinese guide for diagnosis and treatment of migraine. The diagnosis standard of the traditional Chinese and western medicine syndromes is met; the duration of attack is 4-72 hours; the attack is more than or equal to 6 times in the last 3 months. Exclusion criteria: those with drug allergy; those with lesions of important parenchymal organs; migraine with special syndrome type; patients taking analgesics or analgesic-dependent drugs for a long time; pregnant or lactating women.
The treatment method comprises the following steps: the control group orally takes flunarizine hydrochloride capsules and orally takes. 1-2 granules are taken once a day 1 time before sleep. The observation group is added with external ginger white cord essential oil on the basis of the control group, and the external ginger white cord essential oil is applied to the Fengchi acupoint, the Baihui acupoint and the migraine, and the dosage is 0.5 ml/person. 2 weeks are 1 course of treatment, and the treatment effect is evaluated for 2 weeks.
Clinical efficacy evaluation criteria. And (3) healing: the headache disappears after the treatment is finished, and the headache is not repeated after the follow-up visit; the effect is shown: the score is reduced by more than or equal to 50 percent after treatment; the method has the following advantages: the reduction is 20 to 50 percent; and (4) invalidation: the reduction was < 20%.
As a result: control group: 3 cases are cured, 3 cases are obviously effective, 4 cases are ineffective, and the total effective rate is 71.4%. Observation group: 5 cases are cured, 4 cases are obviously effective, 4 cases are effective, 1 case is ineffective, and the total effective rate is 92.8%.
The same experiment is carried out on the example 1 and the examples 2 and 3 at the same time, and the same and similar results are obtained, which shows that the product has good quality and stable and reliable curative effect, and are not listed any more.
Conclusion
The medicine can be used for effectively treating migraine, is easy to produce and prepare, convenient to use and good in effect, is an innovation in the medicine for treating migraine, and has remarkable economic and social benefits.
Claims (4)
1. The externally applied ginger and white thread essential oil for treating migraine is characterized by comprising the following raw materials: 5-7ml of angelica essential oil, 4-6ml of asarum essential oil, 4-6ml of ginger essential oil, 4-6ml of mint essential oil, 2.5-3.5ml of corydalis essential oil and 5-7g of borneol, and dissolving and uniformly mixing to prepare the traditional Chinese medicine; wherein:
the radix angelicae essential oil is prepared by crushing radix angelicae into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the angelica essential oil;
the preparation methods of the asarum essential oil, the ginger essential oil, the mint essential oil and the corydalis essential oil are the same as those of the angelica essential oil.
2. The externally applied ginger white cord essential oil for treating migraine according to claim 1, which is prepared from the following raw materials: 6ml of angelica essential oil, 5ml of asarum essential oil, 5ml of ginger essential oil, 5ml of mint essential oil, 3ml of corydalis essential oil and 6g of borneol, and dissolving and uniformly mixing to prepare the traditional Chinese medicine.
3. The externally applied ginger white cord essential oil for treating migraine according to claim 1, which is prepared from the following raw materials: 5.5ml of angelica essential oil, 5.5ml of asarum essential oil, 4.5ml of ginger essential oil, 5.5ml of mint essential oil, 2.8ml of corydalis essential oil and 6.5g of borneol, and dissolving and uniformly mixing the components to prepare the traditional Chinese medicine.
4. The externally applied ginger white cord essential oil for treating migraine according to claim 1, which is prepared from the following raw materials: 6.5ml of angelica essential oil, 4.5ml of asarum essential oil, 5.5ml of ginger essential oil, 4.5ml of mint essential oil, 3.2ml of corydalis essential oil and 5.5g of borneol, and dissolving and uniformly mixing the components to prepare the traditional Chinese medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911276697.4A CN110841051A (en) | 2019-12-12 | 2019-12-12 | External-use ginger and white-cord essential oil for treating migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911276697.4A CN110841051A (en) | 2019-12-12 | 2019-12-12 | External-use ginger and white-cord essential oil for treating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110841051A true CN110841051A (en) | 2020-02-28 |
Family
ID=69608999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911276697.4A Pending CN110841051A (en) | 2019-12-12 | 2019-12-12 | External-use ginger and white-cord essential oil for treating migraine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110841051A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112316096A (en) * | 2020-11-20 | 2021-02-05 | 湖南中医药大学 | Traditional Chinese medicine volatile oil composition, preparation thereof, preparation method and application of preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370704A (en) * | 2010-08-10 | 2012-03-14 | 东源绿保生物科技开发有限公司 | Compound camellia seed essential oil |
| CN104116769A (en) * | 2014-08-12 | 2014-10-29 | 王学建 | Method for treating headache by using traditional Chinese medicine |
| CN108653435A (en) * | 2018-08-15 | 2018-10-16 | 河南中医药大学 | A kind of essential oil of traditional Chinese medicine for treating allergic rhinitis |
-
2019
- 2019-12-12 CN CN201911276697.4A patent/CN110841051A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370704A (en) * | 2010-08-10 | 2012-03-14 | 东源绿保生物科技开发有限公司 | Compound camellia seed essential oil |
| CN104116769A (en) * | 2014-08-12 | 2014-10-29 | 王学建 | Method for treating headache by using traditional Chinese medicine |
| CN108653435A (en) * | 2018-08-15 | 2018-10-16 | 河南中医药大学 | A kind of essential oil of traditional Chinese medicine for treating allergic rhinitis |
Non-Patent Citations (3)
| Title |
|---|
| 仇铁群: "《女人香疗艾炙美容养颜书》", 28 February 2014, 中国妇女出版社 * |
| 刘正才，等: "《汉方美丽小秘方 对抗文明病》", 31 December 2006, 世界图书出版西安公司 * |
| 王萍等: "中药鼻疗法治疗偏头痛", 《中国中医药信息杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112316096A (en) * | 2020-11-20 | 2021-02-05 | 湖南中医药大学 | Traditional Chinese medicine volatile oil composition, preparation thereof, preparation method and application of preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100444887C (en) | Application of composition for preparing medicine to treat chilblain disease | |
| CN107669991B (en) | Pharmaceutical composition for reducing blood uric acid level and preparation method thereof | |
| CN110841051A (en) | External-use ginger and white-cord essential oil for treating migraine | |
| WO2014079396A1 (en) | Oil mixture for treating acne | |
| CN105943651B (en) | A kind of Chinese medicine composition that treating premature ovarian failure and its application | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN101983644A (en) | Medicament for treating sequelae of apoplexy | |
| CN103520504B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy | |
| CN104606516A (en) | Traditional Chinese medicine for treating migraine | |
| CN104147388A (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN104435669B (en) | The Chinese medicine composition of the concurrent multiple organ dysfunction syndrome for the treatment of septic shock | |
| CN103520550B (en) | Traditional Chinese medicine for treating external cold internal rheum type chronic bronchitis and preparation method thereof | |
| CN102166272A (en) | Medicament for treating hemorrhoids and preparation method thereof | |
| CN111249381A (en) | Application of composition in preparation of medicine for preventing and treating constipation | |
| CN101590114B (en) | Medicament for treating multiple sclerosis and preparation method thereof | |
| CN104435437B (en) | A kind ofly treat Chinese medicine of the concurrent glossopharyngeal neuralgia of trigeminal neuralgia and preparation method thereof | |
| CN105031025B (en) | Compound Chinese medicinal preparation for treating porcine mycoplasmal pneumonia and preparation method thereof | |
| CN114404535B (en) | Pharmaceutical composition for relieving cancer-induced fatigue and chronic fatigue syndrome, and preparation method and application thereof | |
| CN115624543B (en) | Medicine for treating migraine, pharmaceutical composition, preparation method and pharmaceutical application thereof | |
| CN111840494B (en) | Anti-gout traditional Chinese medicine composition, preparation method and application thereof | |
| CN106727937A (en) | It is a kind of to improve the health care of sleep Chinese medicine composition of state and preparation method thereof | |
| CN101632762A (en) | Traditional Chinese medicine ointment for treating child aphtha | |
| CN105288171A (en) | Pharmaceutical composition for treating male climacteric syndrome | |
| CN104189427A (en) | Traditional Chinese medicinal composition for treating wind-cold cough and asthma diseases and application thereof | |
| CN104825808A (en) | Chinese medicinal composition for treating chronic pharyngitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |
|
| RJ01 | Rejection of invention patent application after publication |